Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy

Clinical Infectious Diseases

Volumn 47, Issue 3, 2008, Pages 421-424

  Hare, C Bradley ^a,j   Mellors, John ^b   Krambrink, Amy ^c   Su, Zhaohui ^c   Skiest, Daniel ^d   Margolis, David M ^e   Patel, Sheran S ^b   Barnas, Douglas ^b   Frenkel, Lisa ^f   Coombs, Robert W ^f   Aweeka, Francesca ^a   Morse, Gene D ^g   Haas, David W ^h   Boltz, Valerie ⁱ   Palmer, Sarah ⁱ   Coffin, John ⁱ   Havlir, Diane V ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BAYSTATE MEDICAL CENTER   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF WASHINGTON   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ NATIONAL CANCER INSTITUTE   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; EFAVIRENZ; NEVIRAPINE; RNA; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREDICTIVE VALIDITY; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS RESISTANCE;

ADULT; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 47549090814     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/589867     Document Type: Article

References (16)

1. Glass TR, De Geest S, Weber R, et al. Correlates of self-reported nonadherence to antiretroviral therapy in HIV-infected patients: the Swiss HIV Cohort Study. J Acquir Immune Defic Syndr 2006; 41:385-92.
2. Skiest DJ, Su Z, Havlir DV, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007; 195:1426-36.
3. Palmer S, Boltz V, Maldarelli F, et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS 2006; 20:701-10.
4. Ellis GM, Mahalanabis M, Beck IA, et al. Comparison of oligonucleotide ligation assay and consensus sequencing for detection of drugresistant mutants of human immunodeficiency virus type 1 in peripheral blood mononuclear cells and plasma. J Clin Microbiol 2004;42:3670-4.
5. Leth FV, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses 2006; 22:232-9.
6. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 2001; 15:71-5.
7. Johnson JA, Li JF, Wei X, et al. Baseline detection of low-frequency drug resistance-associated mutations is strongly associated with virologic failure in previously antiretroviral naive HIV-1 infected persons. Antviral Ther 2006; 11:S79.
8. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA 2001; 286:171-9.
9. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS 2004; 18:981-9.
10. Napravnik S, Edwards D, Stewart P, Stalzer B, Matteson E, Eron JJ Jr. HIV-1 drug resistance evolution among patients on potent combination antiretroviral therapy with detectable viremia. J Acquir Immune Defic Syndr 2005; 40:34-40.
11. Dybul M, Nies-Kraske E, Daucher M, et al. Long-cycle structured intermittent versus continuous highly active antiretroviral therapy for the treatment of chronic infection with human immunodeficiency virus: effects on drug toxicity and on immunologic and virologic parameters. J Infect Dis 2003; 188:388-96.
12. Cohen CJ, Morris A, Bazner S, et al. Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week result of the five days on, two days off (FOTO) study. HIV Clin Trials 2007; 8:19-23.
13. Dybul M, Nies-Kraske E, Dewar R, et al. A proof-of-concept study of short-cycle intermittent antiretroviral therapy with a once-daily regimen of didanosine, lamivudine, and efavirenz for the treatment of chronic HIV infection. J Infect Dis 2004; 189:1974-82.
14. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A 2006; 103:7094-9.
15. Barbour JD, Hecht FM, Wrin T, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS 2004; 18:1683-9.
16. Halfon P, Penaranda G, Khiri H, Xerridat B. Long-term persistence of HIV with drug resistance after CD4 cell count-guided structured treatment interruption. AIDS 2005; 19:1713-4.